New whole plant therapy shows promise as an effective and economical treatment for malaria

December 20, 2012

Worcester, Mass. - In the worldwide battle to curtail malaria, one of the most prevalent and deadly infectious diseases of the developing world, drug after drug has fallen by the wayside as the malaria parasite has become resistant to it. Only artemisinin, derived from the sweet wormwood plant, Artemisia annua, remains as an effective treatment, but it is expensive to produce (particularly when combined with other antimalarial medications to make it less prone to resistance) and is frequently in short supply.

A new study by scientists at Worcester Polytechnic Institute (WPI) and the University of Massachusetts has shown that the powdered dried leaves from the Artemisia annua plant may be a far more effective antimalarial treatment than purified artemisinin, delivering 40 times more artemisinin to the blood and reducing the level of parasite infection more completely in mice. The effectiveness of the whole plant, versus the purified drug, may be due, in part, to the presence in Artemisia annua leaves of other compounds, including flavonoids also known to have antimalarial abilities, which may create a combination therapy that works synergistically to combat the parasite and ward off resistance.

These are some of the conclusions of a paper titled "Dried whole plant Artemisia annua as an antimalarial therapy," published online today by the journal PLOS ONE .

Using the dried whole plant, instead of purified artemisinin, could significantly lower the cost of treating malaria, since it would eliminate the need to extract the drug from the plant and purify it, and could greatly expand access to antimalarial therapy, according to Pamela Weathers, professor of biology and biotechnology at WPI and a co-author of the new study. "Artemisia can be grown readily in most climates," she says. "It is a relatively simple process to harvest the leaves, pulverize them, test samples for their potency, measure out doses, and put them in capsules. This could become the basis for local businesses and be a wonderful socioeconomic stimulus in developing countries."

Weathers has been studying the antimalarial abilities of Artemisia annua for more than two decades. She first described the efficacy of using of the whole plant as an antimalarial treatment in a 2011 paper published in Photochemistry Reviews. In the latest study, a high-yield cultivar of the plant developed in her lab was administered to mice by her team, led by Stephen Rich, a molecular parasitologist at the University of Massachusetts Amherst. The effects of the whole plant therapy were compared to the effects of comparable doses of pure artemisinin.

The researchers found that mice receiving a dose of the dried leaves containing a low level of artemisinin showed a significantly greater reduction in blood-borne parasites over the course of 12 to 72 hours than mice receiving the same dose of the pure artemisinin drug. When plant material containing a high level of artemisinin was given to mice, the whole plant was as effective as a high dose of the drug in clearing parasites from the blood. Interestingly, plant material with a low level of artemisinin was as effective in killing parasites as a high dose of the drug, although its effects seemed to wane after 72 hours, suggesting that multiple doses would be necessary to fully treat a malarial infection.

Weathers says the effectiveness of the whole plant treatment seems to be due, in part, to the fact that artemisinin from the dried leaves enters the bloodstream far more readily than the pure drug. "In our 2011 study, we showed that it takes about 40 times less artemisinin to achieve a comparable blood serum level when the compound is administered in the form of the whole plant," she says. "This is consistent with the results of earlier studies in which people consumed teas made from whole leaves from Artemisia annua."

Weathers says the effectiveness of using the whole plant as a therapy is likely a product of the plant's complex biochemistry. "The leaves of Artemisia contain a host of compounds that are of interest for their apparent but lesser antimalarial abilities," she says. "These include at least six flavonoids that have been shown to work synergistically with artemisinin to kill malaria parasites. This makes the artemisia leaves a combination therapy all by themselves. In fact, we have referred to the whole plant as pACT (plant Artemisinin Combination Therapy), to distinguish it from the Artemisinin Combination Therapies (ACT) that are now recommended for malaria treatment by the World Health Organization.

Artemisia annua is classified as a "generally regarded as safe" (GRAS) herb that has been consumed by humans and used as an herbal therapy for thousands of years. Weathers says she has been actively working for several years to establish the foundation for a new model for using whole plant therapy to combat malaria. She said she envisions local operations where farmers would grow the high-producing cultivars of Artemisia she and others have developed as a supplemental crop and deliver the leaves to processing stations, where they would be dried, pulverized, and homogenized, and where the powder would be placed in capsules or compacted into tablets.

"By decentralizing the production of pACT, and giving local farmers and business people the opportunity to earn a living from producing it, we will not only make an effective therapy broadly available at an affordable price, we will help stimulate the economies of developing nations. It is exciting to be involved with a project that can be beneficial in so many ways.

"When you consider that artemisinin and some of the flavonoids in Artemisia annua have been to have a therapeutic effect against host of other diseases, including Leishmania, schistosomiasis, and other ailments that are serious health hazards in the developing world, the long-term possibilities of this research grow exponentially."
-end-
This work was funded by the UMass Medical School Center for Clinical and Translational Science and Worcester Polytechnic Institute.

About Worcester Polytechnic InstituteFounded in 1865 in Worcester, Mass., WPI was one of the nation's first engineering and technology universities. Its 14 academic departments offer more than 50 undergraduate and graduate degree programs in science, engineering, technology, business, the social sciences, and the humanities and arts, leading to bachelor's, master's and doctoral degrees. WPI's talented faculty work with students on interdisciplinary research that seeks solutions to important and socially relevant problems in fields as diverse as the life sciences and bioengineering, energy, information security, materials processing, and robotics. Students also have the opportunity to make a difference to communities and organizations around the world through the university's innovative Global Perspective Program. There are more than 30 WPI project centers throughout North America and Central America, Africa, Australia, Asia, and Europe.

Worcester Polytechnic Institute

Related Combination Therapy Articles from Brightsurf:

Promising results from in vitro combination therapy against COVID-19
Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19.

Combination therapy against cancer
In their quest to destroy cancer cells, researchers are turning to combinational therapies more and more.

Oncotarget: Adoptive cell therapy in combination with checkpoint inhibitors
Volume 11, Issue 22 of @Oncotarget reported that there are rationale and evidence supporting immune therapy in Ovarian Cancers.

Can a combination immune therapy reduce genital herpes outbreaks?
New Haven, Conn. -- Yale investigators have shown that the combination of a vaccine and a medicated cream is a promising strategy to dramatically reduce the recurrence of genital herpes.

New combination therapy established as safe and effective for prostate cancer
A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting.

Combination therapy advisable for bowel disorder IBS
The more abnormalities in intestinal and brain function that IBS sufferers have, the more severe their symptoms of this functional bowel disorder, and the more adversely their everyday life is affected.

CD40 combination therapy can shrink pancreatic tumors
A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients.

Combination therapy treats leishmaniasis, HIV patients
Coinfection with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) has been observed in at least 35 countries on four continents and requires special case management.

Combination gene therapy more effective in cartilage preservation in osteoarthritis
A combinatorial gene therapy approach -- one designed to inhibit inflammation and one targeting protection against cartilage degeneration -- was shown to preserve articular carti-lage better than each approach alone in animal models of both moderate and severe post-traumatic osteoarthritis.

Combination therapy promising against blindness-causing bacterial keratitis
Multidrug-resistant bacterial infections of the cornea are a leading cause of blindness and cannot be effectively managed with current ophthalmic antibiotics.

Read More: Combination Therapy News and Combination Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.